FOURTH AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • March 14th, 2023 • Cellectis S.A. • Biological products, (no disgnostic substances)
THIS FOURTH AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT (the “Fourth Amendment”) is made and entered effective as of the date of the last signature (the “Third Amendment Effective Date”), by and between Regents of the University of Minnesota (the “University”), a Minnesota constitutional corporation under the laws of the state of Minnesota, and Cellectis S.A, a Corporation under the laws of the France having a place of business at 8, rue de la Croix Jarry, 75013 Paris, France (the “Licensee” or “Cellectis”) each a “Party” and collectively, the “Parties”).
FORM OF [FIRST AMENDMENT TO THE] CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 14th, 2023 • Cellectis S.A. • Biological products, (no disgnostic substances) • Delaware
[This First Amendment to the Change in Control Agreement (the “Amendment”)] / [This Change in Control Agreement (the “Agreement”)] is made as of ___, 2022, by and between [EXECUTIVE NAME] (the “Executive”) and [INSERT] (the “Company”).
ContractFinance Contract • March 14th, 2023 • Cellectis S.A. • Biological products, (no disgnostic substances)
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private and confidential.
